|
|
|
|
|
Legal status
Patent lapsed (non-payment of fees)
| (51) | INT.CL. | C07J 9/00 | (2006.01) |
| A61K 31/56 | (2006.01) |
| (11) | Number of the document | 1776377 |
| (13) | Kind of document | T |
| (96) | European patent application number | 05715596.2 |
| Date of filing the European patent application | 2005-02-28 | |
| (97) | Date of publication of the European application | 2007-04-25 |
| (45) | Date of publication and mention of the grant of the patent | 2008-07-30 |
| (46) | Date of publication of the claims translation | 2009-03-25 |
| (86) | Number | PCT/EP2005/002086 |
| Date | 2005-02-28 |
| (87) | Number | WO 2005/082925 |
| Date | 2005-09-09 |
| (30) | Number | Date | Country code |
| 04004408 | 2004-02-26 | EP |
| (72) |
PELLICCIARI, Roberto, IT
|
| (73) |
Intercept Pharmaceuticals, Inc.,
421 Hudson Street, Suite 212, New York, NY 10014,
US
|
| (74) |
Reda ŽABOLIENĖ,
METIDA, Verslo centras "VERTAS", Gynėjų g. 16, LT-01109 Vilnius,
LT
|
| (54) | Naujieji FXR steroidų agonistai |
| NOVEL STEROID AGONIST FOR FXR |
| Payment date | Validity (years) | Amount | |
| 2021-02-02 | 17 | 347.00 EUR |
| Patent lapsed (non-payment of fees) | ||
| Invalidation date | 2022-02-28 |